(Q51037125)

27 March 2018

title

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia (English)

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

15 July 2024

0 references

1 reference

cognitive dysfunction

1 reference

based on heuristic

inferred from title

author name string

Jean-Pierre Lindenmayer

1

1 reference

27 March 2018

Anzalee Khan

2

1 reference

27 March 2018

language of work or name

English

0 references

publication date

17 September 2010

1 reference

27 March 2018

full work available at URL

number of pages

11

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0920996410014921?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

https://api.elsevier.com/content/article/PII:S0920996410014921?httpAccept=text/plain

15 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

15 July 2024

published in

Schizophrenia Research

1 reference

27 March 2018

volume

125

1 reference

27 March 2018

issue

2-3

1 reference

27 March 2018

page(s)

267-277

1 reference

27 March 2018

A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Galantamine for treatment-resistant schizophrenia

15 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.

15 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia

15 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Galantamine for the treatment of cognitive impairments in people with schizophrenia

15 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment

15 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

15 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies

15 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits

15 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

What are the functional consequences of neurocognitive deficits in schizophrenia?

15 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

15 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia

15 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Understanding the diagnostic capabilities of cognitive tests.

15 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

15 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

15 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Five-factor model of schizophrenia. Initial validation

15 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

The effects of AMPA-induced lesions of the septo-hippocampal cholinergic projection on aversive conditioning to explicit and contextual cues and spatial learning in the water maze.

15 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

15 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands

15 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

15 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

15 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release

15 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.SCHRES.2010.08.021

15 July 2024

Identifiers

1 reference

27 March 2018

1 reference

27 March 2018